Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)	$ 5,863	$ 27,588	$ (11,938)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Stock-based compensation	24,195	21,358	17,649
Interest on liability for sale of future royalties	14,449	16,172	185
Sold portion of royalty revenue	(12,811)	(10,234)	(2,103)
Write-off of inventory	10,397	3,855	4,574
Depreciation and amortization	12,284	7,371	4,535
Loss (gain) on foreign currency transaction	7,749	(3,907)	1,916
Impairment loss on available-for-sale investment	6,409	1,550	170
Net accretion of investments	(2,647)	(5,092)	(925)
Non-cash lease expense of right-of-use assets	1,212	1,668	1,301
Change in fair value of contingent liability	1,029
Amortization of debt discount and issuance costs	854	1,646	2,085
Loss on settlement of debt		20,444
Gain on bargain purchase		(5,259)
Loss on estimated returns of acquired product		1,444
Other, net	155	380	(84)
Change in deferred tax liability	(4,969)
Changes in operating assets and liabilities:
Accounts receivable, net	(4,762)	2,652	2,345
Inventory	(6,624)	(3,196)	(11,347)
Prepaid expenses and other current assets	(10,032)	(6,574)	(7,318)
Other assets	(1,909)	(3,570)	263
Accounts payable	(16,711)	(2,788)	(1,473)
Accrued expenses and other current liabilities	3,256	(2,703)	6,606
Deferred revenue	(8,259)	(15,312)	39,462
Recognized loss on purchase commitments		(2,690)	(9,424)
Operating lease liabilities	(873)	(2,292)	(2,385)
Net cash provided by operating activities	18,255	42,511	34,094
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of available-for-sale securities	(157,803)	(7,006)
Proceeds from maturities of available-for-sale securities	215,308	58,126
Acquisition of scPharma, net of cash acquired	(347,742)
Issuance of note receivable	(10,000)
Purchase of property and equipment	(4,566)	(9,693)	(42,441)
Purchase of held-to-maturity securities		(273,789)	(79,095)
Proceeds from maturities of held-to-maturity securities		135,317	119,166
Proceeds from insurance claim		396	382
Net cash used in investing activities	(304,803)	(96,649)	(1,988)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from term loan	325,000
Payment of loan issuance costs	(7,266)
Payments for taxes related to net issuance of common stock associated with restricted stock units and stock options	(3,262)	(6,087)	(10,162)
Principal payments on financing liability	(726)	(398)	(189)
Proceeds from market price stock purchase plan and employee stock purchase plan	1,992	3,139	1,820
Milestone Right Agreement payment	(639)	(752)	(924)
Principal and early extinguishment payments on MidCap credit facility		(36,617)	(6,667)
Proceeds from sale of future royalties			150,000
Issuance costs associated with sale of future royalties			(4,050)
Principal and early extinguishment payments on senior convertible notes		(87,697)
Principal and early extinguishment payments on Mann Group convertible note		(8,854)
Net cash provided by (used in) financing activities	315,099	(137,266)	136,607
NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	28,551	(191,404)	168,713
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING OF PERIOD	47,076	238,480	69,767
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, END OF PERIOD	75,627	47,076	238,480
SUPPLEMENTAL CASH FLOWS DISCLOSURES:
Interest paid in cash	14,716	17,506	18,279
Income taxes paid in cash	1,705	4,262
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Non-cash contingent consideration from acquisition of scPharma	25,217
Debt forgiven as part of scPharma acquisition	10,000
Payments of senior convertible note principal through common stock issuances		116,439
Amortization of liability for sale of future royalties	1,407	3,605
Purchases of property and equipment included in accounts payable and accrued expenses	$ 619	1,679	1,691
Assumption of right-of-use-asset and operating lease liability		10,057
Non-cash acquisition of intangible asset		4,300
Non-cash acquisition of property and equipment		959
Right-of-use asset modification			728
Goodwill adjustment for a net reduction in liabilities			497
Receivable for insurance claim on damaged equipment			445
Accrued issuance costs associated with liability for sale of future royalties			325
The Mann Group L L C
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Payments of Mann Group principal and interest through common stock issuances		$ 3,806	222
At The Market Issuance
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from at-the-market-offering			6,887
Issuance costs associated with at-the-market offering			$ (108)